Rare Disease CROs in United Kingdom

CDMO headquartered in Northern Ireland providing GMP API synthesis, drug product development, clinical trial supply manufacturing, and biomarker services across North America and Europe.

UK nonclinical safety CRO founded by former AstraZeneca scientists, specializing in integrated toxicology and ion channel electrophysiology studies for regulatory drug safety assessment.

UK-headquartered global mid-size CRO (now part of LabCorp/Covance) with deep expertise in oncology, rare diseases, and paediatric clinical trials across 30+ countries.

Mid-size global CRO acquired by Labcorp providing clinical development services from Phase I through Phase IV with operations across Europe, Asia, and the Americas.

Glasgow-founded, India-expanded full-service CRO providing clinical trial management, site management, and regulatory services across Asia-Pacific, Europe, and North America.

Labcorp Drug Development's UK preclinical facility providing GLP toxicology, safety pharmacology, and reproductive toxicology studies from Harrogate, North Yorkshire.

Global full-service CRO specializing in oncology, rare disease, and complex clinical trials across all development phases, with 2,900+ clinical research professionals operating in 100+ countries.

Award-winning specialist biometrics CRO headquartered in London, providing biostatistics, statistical programming, data management, and analytics to global pharma, biotech, and device companies.

One of the world's largest data-focused biometrics CROs, providing biostatistics, statistical programming, clinical data management, and medical writing without conducting clinical operations.

Translational pharmaceutics CRO integrating drug substance, drug product, and clinical testing in a single facility. Specializes in formulation development with integrated Phase 1 studies.

Cell and gene therapy CDMO with purpose-built cGMP facilities in Edinburgh and Hopkinton, Massachusetts, supporting clinical and commercial advanced therapy programs.

Full-service boutique CRO with a purpose-built MHRA-accredited Phase I unit in South Wales. Specializes in early-phase clinical pharmacology, oncology, rare diseases, and respiratory conditions through to Phase III.